A San Jose, California-based company appears to be the first in the US to routinely offer nanopore sequencing as part of a testing lab service.
The firm is part of a research consortium that is led by Mount Sinai and includes Fluidigm to develop a device to detect epigenetic signatures of WMD exposure.
Cyclomics, a 2018 spinout from University Medical Center Utrecht, is testing its assay for treatment response and recurrence monitoring in head and neck cancer.
The test will run on Oxford Nanopore's MinIon and will be used as a reflex test when the standard PCR test does not give a clear answer.
The researchers are testing the method in a clinical trial of hospital-acquired pneumonia and are working on tests for meningitis and prosthetic joint infections.
Using a protocol developed at the University of Oxford, the researchers hope that nanopore sequencing can aid diagnosis and drug resistance profiling in remote areas.
Researchers have shown that metagenomic sequencing on the MinIon can identify the pathogen and antimicrobial resistance profile of UTIs in several hours.